Relma-cel for Moderate to Severe Active Systemic Lupus Erythematosus Single Arm Phase I and Phase II Randomized Controlled Open, Multicenter Study.

A clinical trial, NCT06297408, is being conducted in China to assess the safety and effectiveness of Relma-cel in treating moderate to severe active systemic lupus erythematosus (SLE). The trial aims to compare the efficacy of Relma-cel with conventional therapy. The study is currently in the interventional phase and is not yet recruiting participants. The estimated completion date for the trial is May 2026. The eligibility criteria for the study include age, diagnosis of SLE, active disease despite previous treatments, and specific requirements related to organ function, infection history, contraceptive use, and exclusion criteria such as previous CAR-T cell therapy or major organ transplantation. The study is being conducted by Shanghai Ming Ju Biotechnology Co., Ltd. and further information can be obtained from JW Medical. [Extracted from the article]